Moderate Plaque Psoriasis
AX-158 receives clinical trial authorization for phase 2a psoriasis study in UK
AX-158 has received clinical trial authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for a phase 2a psoriasis study, Artax Biopharma announced in a press release.
Salicylic acid, ceramides-containing moisturizers may be adjuvant therapies for psoriasis
Salicylic acid and ceramides-containing skincare products may soften psoriatic plaques, allowing for improved absorption of topical treatments, suggesting skin care may play a role in managing psoriasis, according to a study.
FDA expands approval of secukinumab for nonradiographic axial spondyloarthritis
The FDA has expanded the approval of secukinumab to include treatment of active nonradiographic axial spondyloarthritis, allowing this drug to treat patients across the entire axSpA spectrum.
Phase 2 trial supports weight-based Otezla dosing in pediatric patients with psoriasis
An improvement in Psoriasis Area and Severity Index scores occurred as early as week 2 in a phase 2 trial of adolescent patients with moderate to severe plaque psoriasis treated with Otezla 20 mg or 30 mg twice daily, leading researchers to support the use of weight-based dosing in children and adolescents, according to analysis in Journal of the American Academy of Dermatology.